Head-to-head comparisons of medication uses, side effects, warnings, and more.
Trulicity (dulaglutide)
Mounjaro (tirzepatide)
Trulicity (dulaglutide)
Mounjaro (tirzepatide)
Summary of Trulicity vs. Mounjaro
Summary for GLP-1 agonist
Prescription only
Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) agonist that helps control blood sugar in people 10 years and older with Type 2 diabetes. It's also approved to lower the risk of heart problems like heart attacks, strokes, and heart-related death in certain adults with Type 2 diabetes. The medication is injected under the skin once a week. Common side effects include nausea, vomiting, diarrhea, and stomach pain. When taken with certain diabetes medications like insulin, there's a higher risk of low blood sugar (hypoglycemia).
Summary for GIP and GLP-1 agonist
Prescription only
Mounjaro (tirzepatide) is a prescription injection that's used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes. Mounjaro (tirzepatide) was approved by the FDA in May 2022 as the first one in a new class of medications called GIP and GLP-1 agonists. The dosage is convenient because it's injected under the skin once a week. Some common side effects of Mounjaro (tirzepatide) include nausea, vomiting, and diarrhea.
Indications of Trulicity vs. Mounjaro
Indications for
•Manage Type 2 diabetes in people 10 years and older, along with diet and exercise
•Lower the risk of heart problems like heart attack, stroke, or death in adults with Type 2 diabetes who have heart disease or heart-related risk factors